Navigation Links
FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older
Date:12/30/2011

SILVER SPRING, Md., Dec. 30, 2011 /PRNewswire-USNewswire/ -- Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Pneumococcal pneumonia, caused when the bacterium Streptococcus pneumoniae infects the lungs, is the most common disease caused by this bacterium in adults. When the bacterium invades parts of the body that are normally free from germs, such as the blood or spinal fluid, the disease is considered "invasive."

"According to recent information for the United States, it is estimated that approximately 300,000 adults 50 years of age and older are hospitalized yearly because of pneumococcal pneumonia," said Karen Midthun, M.D., director of FDA's Center for Biologics Evaluation and Research. "Pneumococcal disease is a substantial cause of illness and death. Today's approval provides an additional vaccine for preventing pneumococcal pneumonia and invasive disease in this age group."  

The new use for Prevnar 13 was approved under the agency's accelerated approval pathway, which allows for earlier approval of treatments for serious and life-threatening illnesses. The pathway allows for the demonstration of effectiveness of a vaccine using an immune marker that is reasonably likely to predict clinical benefit.

In randomized, multi-center studies in the United States and Europe, people 50 and older received either Prevnar 13 or Pneumovax 23, a licensed pneumococcal vaccine also approved for use in this age group. The studies showed that for the 12 common serotypes, Prevnar 13 induced antibody levels that were either comparable to or higher than the levels induced by Pneumovax 23.

The safety of Prevnar 13 was evaluated in about 6,000 people ages 50 and older who received Prevnar 13 and who had and had not previously received Pneumovax 23. Common adverse reactions reported with Prevnar 13 were pain, redness, and swelling at the injection site, limitation of movement of the injected arm, fatigue, headache, chills, decreased appetite, generalized muscle pain, and joint pain. Similar reactions were observed in those who received Pneumovax 23.

Accelerated approval is granted on the condition that a clinical trial is conducted during the post-approval marketing of the vaccine to verify the anticipated clinical benefit. An additional trial in 85,000 people ages 65 and older, with no previous history of receiving Pneumovax 23, is underway to confirm the clinical benefit of Prevnar 13 in the prevention of pneumococcal pneumonia.

Prevnar 13 is already approved for use in children ages 6 weeks through 5 years for the prevention of invasive disease caused by 13 different serotypes of the bacterium Streptococcus pneumoniae and for the prevention of otitis media caused by seven of the serotypes of the bacterium.  

The approval of Prevnar 13 for adults 50 years and older supports the Department of Health and Human Services' Healthy People 2020 objectives

Prevnar 13 is manufactured by Collegeville, Pa.-based Wyeth Pharmaceuticals.

For more information:

PREVNAR 13

Healthy People 2020

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Rita Chappelle, 301-796-4672, rita.chappelle@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
2. FDA Expands Use of HIV Drug Isentress to Children and Adolescents
3. Radient Pharmaceuticals Corporation Expands Distribution of Onko-Sure® in Asia; Receives Payment on First Order of 60 Kits
4. Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe
5. Lilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools
6. Sony Expands Radiology Product Offerings with Full Line of Diagnostic Displays
7. Leading Indian CRO Max Neeman International Expands in Response to Positive Biosimilars Market in India
8. Panasonic Expands on Hearing Instrument Lineup
9. Gaylord Sleep Medicine Expands Sleep Apnea Management Program
10. Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test for an Additional Investigational Cancer Immunotherapy Antigen
11. Free Statewide Rx Assistance Program Expands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
(Date:4/28/2016)... , April 28, 2016 ... , George Phillips und ... Unternehmens    ArisGlobal®, ein führender ... Sciences, gab heute bekannt, dass neue Führungskräfte ... Unternehmens gestoßen sind, die vielfältige Erfahrungen mitbringen. ...
(Date:4/28/2016)... Ind., April 28, 2016 , Net Sales ... reported basis over the prior year period, and an increase ... , Diluted EPS for the first quarter were $0.52 ... and $2.00 adjusted, an increase of 29.9% over the prior ... and adjusted earnings guidance for 2016 Zimmer Biomet ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... 30, 2016 , ... Dr. Trevor Gardner, President of the ... a multifaceted agreement which will allow for the research and development of medical ... and Applied Sciences, Allied Health and Nursing will work together to develop new ...
(Date:4/29/2016)... Dobbs Ferry, New York (PRWEB) , ... April 30, 2016 , ... ... and the Dobbs Ferry campus. The following programs will be expanding due to ... Resources Management (HRM). The expansion will begin this summer. , School ...
(Date:4/29/2016)... ... ... Our bodies are bombarded daily by environmental and lifestyle factors that can ... to adopt a more healthful diet, but too many people think that food has ... and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees whole-heartedly. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) ... with sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, ... Run and Walk and 1-mile walk were held to increase awareness about Lyme ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
Breaking Medicine News(10 mins):